Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1986 Jul 1;135(1):27–32.

Postmarketing surveillance of adverse drug reactions: problems and solutions.

F M Lortie
PMCID: PMC1491132  PMID: 3719483

Abstract

The surveillance of adverse drug reactions (ADRs) is an unqualified must. However, the optimal means of surveillance is still unclear. Although anecdotal reports are the backbone of an ADR surveillance system, they are not enough. The pharmaceutical industry, academics and regulatory agencies need to expand their efforts in monitoring ADRs. The author discusses the various techniques for counting and evaluating adverse reactions and suggests ways in which the system could be improved.

Full text

PDF
27

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barclay W. R. Adverse drug reactions. JAMA. 1979 Aug 17;242(7):656–656. [PubMed] [Google Scholar]
  2. Curb J. D., Borhani N. O., Blaszkowski T. P., Zimbaldi N., Fotiu S., Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985 Jun 14;253(22):3263–3268. [PubMed] [Google Scholar]
  3. Feinstein A. R. Clinical biostatistics. XX. The epidemiologic trohoc, the ablative risk ratio, and "retrospective" research. Clin Pharmacol Ther. 1973 Mar-Apr;14(2):291–307. doi: 10.1002/cpt1973142291. [DOI] [PubMed] [Google Scholar]
  4. Feinstein A. R. Methodologic problems and standards in case-control research. J Chronic Dis. 1979;32(1-2):35–41. doi: 10.1016/0021-9681(79)90009-2. [DOI] [PubMed] [Google Scholar]
  5. Freilich W. B. Legal perspectives in causality assessment. Drug Inf J. 1984;18(3-4):211–217. doi: 10.1177/009286158401800304. [DOI] [PubMed] [Google Scholar]
  6. Gifford L. M., Aeugle M. E., Myerson R. M., Tannenbaum P. J. Cimetidine postmarket outpatient surveillance program. Interim report on phase I. JAMA. 1980 Apr 18;243(15):1532–1535. [PubMed] [Google Scholar]
  7. Goldsmith M. F. Postmarketing follow-up: physicians have key role. JAMA. 1985 Oct 25;254(16):2217–2217. [PubMed] [Google Scholar]
  8. Gowdey C. W., Brennan M. Adverse Drug Reaction Reporting Program of the Ontario Medical Association: the first 3 years. Can Med Assoc J. 1985 Jan 1;132(1):19–23. [PMC free article] [PubMed] [Google Scholar]
  9. Griffin J. P. Is better feedback a major stimulus to spontaneous adverse reaction monitoring? Lancet. 1984 Nov 10;2(8411):1098–1098. doi: 10.1016/s0140-6736(84)91535-6. [DOI] [PubMed] [Google Scholar]
  10. HILL A. B. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med. 1965 May;58:295–300. doi: 10.1177/003591576505800503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hayden G. F., Kramer M. S., Horwitz R. I. The case-control study. A practical review for the clinician. JAMA. 1982 Jan 15;247(3):326–331. [PubMed] [Google Scholar]
  12. Hutchinson T. A., Leventhal J. M., Kramer M. S., Karch F. E., Lipman A. G., Feinstein A. R. An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA. 1979 Aug 17;242(7):633–638. [PubMed] [Google Scholar]
  13. Ibrahim M. A., Spitzer W. O. The case control study: the problem and the prospect. J Chronic Dis. 1979;32(1-2):139–144. doi: 10.1016/0021-9681(79)90026-2. [DOI] [PubMed] [Google Scholar]
  14. Inman W. H. Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton. Br Med J (Clin Res Ed) 1981 Apr 11;282(6271):1216–1217. doi: 10.1136/bmj.282.6271.1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jones J. K., Van de Carr S. W., Rosa F., Morse L., LeRoy A. Medicaid drug-event data: an emerging tool for evaluation of drug risk. Acta Med Scand Suppl. 1984;683:127–134. doi: 10.1111/j.0954-6820.1984.tb08728.x. [DOI] [PubMed] [Google Scholar]
  16. Karch F. E., Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977 Mar;21(3):247–254. doi: 10.1002/cpt1977213247. [DOI] [PubMed] [Google Scholar]
  17. Koch-Weser J., Sellers E. M., Zacest R. The ambiguity of adverse drug reactions. Eur J Clin Pharmacol. 1977 Jan 3;11(2):75–78. doi: 10.1007/BF00562895. [DOI] [PubMed] [Google Scholar]
  18. Louik C., Lacouture P. G., Mitchell A. A., Kauffman R., Lovejoy F. H., Jr, Yaffe S. J., Shapiro S. A study of adverse reaction algorithms in a drug surveillance program. Clin Pharmacol Ther. 1985 Aug;38(2):183–187. doi: 10.1038/clpt.1985.156. [DOI] [PubMed] [Google Scholar]
  19. Lyon R. A. Adverse drug effects: evaluation of four secondary reference sources. Hosp Formul. 1985 Mar;20(3):315-7, 320-1. [PubMed] [Google Scholar]
  20. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  21. Miettinen O. S. Matching and design efficiency in retrospective studies. Am J Epidemiol. 1970 Feb;91(2):111–118. doi: 10.1093/oxfordjournals.aje.a121118. [DOI] [PubMed] [Google Scholar]
  22. Moore N., Biour M., Paux G., Loupi E., Begaud B., Boismare F., Royer R. J. Adverse drug reaction monitoring: doing it the French way. Lancet. 1985 Nov 9;2(8463):1056–1058. doi: 10.1016/s0140-6736(85)90918-3. [DOI] [PubMed] [Google Scholar]
  23. Naranjo C. A., Busto U., Sellers E. M., Sandor P., Ruiz I., Roberts E. A., Janecek E., Domecq C., Greenblatt D. J. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239–245. doi: 10.1038/clpt.1981.154. [DOI] [PubMed] [Google Scholar]
  25. Roos L. L., Jr, Roos N. P., Cageorge S. M., Nicol J. P. How good are the data? Reliability of one health care data bank. Med Care. 1982 Mar;20(3):266–276. doi: 10.1097/00005650-198203000-00003. [DOI] [PubMed] [Google Scholar]
  26. Rossi A. C., Knapp D. E., Anello C., O'Neill R. T., Graham C. F., Mendelis P. S., Stanley G. R. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. JAMA. 1983 Apr 22;249(16):2226–2228. doi: 10.1001/jama.249.16.2226. [DOI] [PubMed] [Google Scholar]
  27. Rossi A. C., Knapp D. E. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. JAMA. 1984 Aug 24;252(8):1030–1033. [PubMed] [Google Scholar]
  28. Sartwell P. E. Retrospective studies. A review for the clinician. Ann Intern Med. 1974 Sep;81(3):381–386. doi: 10.7326/0003-4819-81-3-381. [DOI] [PubMed] [Google Scholar]
  29. Shapiro S. The epidemiological evaluation of drugs. Acta Med Scand Suppl. 1984;683:23–27. doi: 10.1111/j.0954-6820.1984.tb08710.x. [DOI] [PubMed] [Google Scholar]
  30. Skegg D. C., Doll R. Record linkage for drug monitoring. J Epidemiol Community Health. 1981 Mar;35(1):25–31. doi: 10.1136/jech.35.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Strom B. L., Carson J. L., Morse M. L., LeRoy A. A. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Clin Pharmacol Ther. 1985 Oct;38(4):359–364. doi: 10.1038/clpt.1985.188. [DOI] [PubMed] [Google Scholar]
  32. Strom B. L., Melmon K. L., Miettinen O. S. Postmarketing studies of drug efficacy. Arch Intern Med. 1985 Oct;145(10):1791–1794. [PubMed] [Google Scholar]
  33. Taggart A. J., Taggart H. Drug safety. Lancet. 1984 Nov 10;2(8411):1098–1099. doi: 10.1016/s0140-6736(84)91536-8. [DOI] [PubMed] [Google Scholar]
  34. Venning G. R. Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? Br Med J (Clin Res Ed) 1983 Jan 15;286(6360):199–202. doi: 10.1136/bmj.286.6360.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Venning G. R. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed) 1983 Feb 5;286(6363):458–460. doi: 10.1136/bmj.286.6363.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Venning G. R. Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions. Br Med J (Clin Res Ed) 1983 Feb 12;286(6364):544–547. doi: 10.1136/bmj.286.6364.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Venulet J. Aspects of standardization as applied to the assessment of drug-event associations. Drug Inf J. 1984;18(3-4):199–210. doi: 10.1177/009286158401800303. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES